mProX™ Human HAVCR2 Stable Cell Line

Product Information

Target Family

Immune Checkpoint

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;Human primary myometrial cells

Target Classification

Immune Checkpoint Cell Lines

Target Research Area

Immunology Research

Related Diseases

T-Cell Lymphoma, Subcutaneous Panniculitis-Like; Hepatitis A

Gene ID

Human:84868

UniProt ID

Human:Q8TDQ0

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The application of HAVCR2 (also known as TIM-3) has been studied in various contexts. In one study, HAVCR2 was found to be one of the ferroptosis-related long non-coding RNAs (FRLncs) that can influence the prognosis and immune microenvironment in osteosarcoma (OS). The study identified seven FRLncs, including HAVCR2, that could serve as potential prognostic markers and influence factors of the immune microenvironment in OS. Another study investigated the potential impact of HAVCR2 on the tumor microenvironment (TME) in pancreatic cancer. The study found that S100P, a member of the S100 protein family, was associated with an immunosuppressive microenvironment in pancreatic cancer and strongly correlated with HAVCR2 expression. Additionally, HAVCR2 was identified as one of the immune checkpoint-related genes linked to OS prognosis. In colorectal cancer, HAVCR2 was found to be associated with the immunological microenvironment, drug sensitivity, and ferroptosis inhibition. The study identified TIMP1 as a valuable biomarker for colorectal cancer and revealed its positive correlation with HAVCR2 expression. Furthermore, HAVCR2 blockade in diffuse intrinsic pontine glioma (DIPG) models promoted tumor regression and antitumor immune memory. The study demonstrated that inhibition of HAVCR2 in DIPG prolonged survival and produced long-term survivors free of disease that harbored immune memory. These findings suggest that HAVCR2 has potential applications in prognostic markers, immunosuppressive microenvironment, drug sensitivity, and antitumor immune response.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human HAVCR2 Stable Cell Line (S01YF-1023-PY187). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Skyler Brown (Verified Customer)

What is the role of HAVCR2 in immune cell activities? Mar 29 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

HAVCR2, encoding the immune modulator TIM-3, plays a significant role in preventing autoimmune reactions and inhibiting NK and T cell functions, suggesting its importance in immune regulation. Mar 29 2022

chat Morgan Garcia (Verified Customer)

How does HAVCR2 mutation affect lymphoma and hemophagocytic lymphohistiocytosis? May 22 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

Germline loss-of-function mutations in HAVCR2 characterize subcutaneous panniculitis-like T cell lymphomas and hemophagocytic lymphohistiocytosis, indicating its critical role in these conditions. May 22 2021

Published Data

Fig.1 The impact of siHAVCR2 on the expression and secretion of pro-inflammatory cytokines and chemokines is examined.

The expression and secretion of pro-inflammatory cytokines and chemokines in primary myometrial cells were investigated in this study by transfecting human primary myometrial cells with 200 nmol/L siHAVCR2 or siCONT for 48 h, followed by treatment with 5 μg/mL poly(I:C) for an additional 24 h (n=5 patients). The mRNA expression of TNF, IL1A, IL1B, IL6, CXCL8, and CCL2 was analyzed by qRT-PCR, and the concentration of IL6 and CXCL8 in the incubation medium was measured using ELISA. The fold change in all data was calculated relative to poly(I:C)-stimulated siCONT-transfected cells, and mean±SEM values were displayed. Significantly, *P<.05 differences were observed compared to poly(I:C)-stimulated siCONT-transfected cells as determined by one-way ANOVA.

Ref: Liong, Stella, et al. "Hepatitis A virus cellular receptor 2 (HAVCR 2) is decreased with viral infection and regulates pro-labour mediators OA." American Journal of Reproductive Immunology 78.1 (2017): e12696.

Pubmed: 28466996

DOI: 10.1111/aji.12696

Research Highlights

Yang, Mingyi. et al. "Ferroptosis-related lncRNAs guiding osteosarcoma prognosis and immune microenvironment." Journal of orthopaedic surgery and research, 2023.
This study aimed to investigate the role of ferroptosis-related long non-coding RNAs (FRLncs) in osteosarcoma (OS) and their potential impact on prognostic and immune microenvironment. The researchers conducted a comprehensive analysis to establish a framework that can guide clinical decision-making in OS management. The findings of this study have significant implications for understanding the molecular mechanisms underlying OS and may pave the way for more effective treatments for this cancer.
Yang, Mingyi. et al. "Ferroptosis-related lncRNAs guiding osteosarcoma prognosis and immune microenvironment." Journal of orthopaedic surgery and research, 2023.
Pubmed: 37858131 DOI: 10.1186/s13018-023-04286-3

Hao, Weiwei. et al. "S100P as a potential biomarker for immunosuppressive microenvironment in pancreatic cancer: a bioinformatics analysis and in vitro study." BMC cancer, 2023.
The impact of immunosuppression on cancer prognosis has been extensively studied, with S100P, a member of the S100 protein family, being implicated in various malignancies. However, the exact role of S100P in the tumor microenvironment (TME) of pancreatic cancer requires further research. This current study focuses on investigating the potential effects of S100P on TME characteristics in patients with pancreatic cancer, aiming to gain insight into its involvement in the disease.
Hao, Weiwei. et al. "S100P as a potential biomarker for immunosuppressive microenvironment in pancreatic cancer: a bioinformatics analysis and in vitro study." BMC cancer, 2023.
Pubmed: 37853345 DOI: 10.1186/s12885-023-11490-1